Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aeterna Zentaris Inc T.AEZS

Alternate Symbol(s):  AEZS

Healthcare Biotechnology
Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The Company is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The... see more

Recent & Breaking News (TSX:AEZS)

Aeterna Zentaris Reports Second Quarter 2013 Financial and Operating Results

Canada NewsWire August 8, 2013

Aeterna Zentaris to Present at Upcoming Canaccord Genuity Global Growth Conference in Boston

Canada NewsWire August 7, 2013

Aeterna Zentaris to Announce Second Quarter 2013 Financial and Operating Results on August 8, 2013

Canada NewsWire August 1, 2013

Aeterna Zentaris: First Patient Dosed for Phase 3 Registration Trial in Endometrial Cancer with Zoptarelin Doxorubicin (AEZS-108)

Canada NewsWire July 31, 2013

Aeterna Zentaris Completes $7.8 Million Registered Direct Offering

Canada NewsWire July 30, 2013

Aeterna Zentaris to Raise US$7.8 Million in Registered Direct Offering

Canada NewsWire July 25, 2013

RDInvesting Provides Investors with Free In-Depth Equity Reports on AEZS, ARPI, NCR and YY

Accesswire July 10, 2013

Aeterna Zentaris Announces Dismissal of Class Action Lawsuit

Canada NewsWire June 6, 2013

Aeterna Zentaris Announces Dismissal of Class Action Lawsuit

PR Newswire June 6, 2013

Aeterna Zentaris: Encouraging Final Data for Phase 1 Portion of Ongoing Phase 1/2 Trial with Zoptarelin Doxorubicin (AEZS-108) in Prostate Cancer Reported at ASCO

PR Newswire June 3, 2013

Aeterna Zentaris: Encouraging Final Data for Phase 1 Portion of Ongoing Phase 1/2 Trial with Zoptarelin Doxorubicin (AEZS-108) in Prostate Cancer Reported at ASCO

Canada NewsWire June 3, 2013

Aeterna Zentaris: Posters to be Presented on Phase 1 and Phase 2 Trials with AEZS-108 in Prostate and Breast Cancer at Upcoming ASCO Meeting

PR Newswire May 23, 2013

Aeterna Zentaris: Posters to be Presented on Phase 1 and Phase 2 Trials with AEZS-108 in Prostate and Breast Cancer at Upcoming ASCO Meeting

Canada NewsWire May 23, 2013

Aeterna Zentaris Announces "At-the-Market" Issuance Program

Canada NewsWire May 21, 2013

Aeterna Zentaris Announces "At-the-Market" Issuance Program

PR Newswire May 21, 2013

Aeterna Zentaris to Present at Upcoming Bloom Burton & Co. Healthcare Investor Conference in Toronto

PR Newswire May 15, 2013

Aeterna Zentaris to Present at Upcoming Bloom Burton & Co. Healthcare Investor Conference in Toronto

Canada NewsWire May 15, 2013

Aeterna Zentaris Announces Election of Directors at its Annual Meeting of Shareholders

Canada NewsWire May 8, 2013

Aeterna Zentaris Announces Election of Directors at its Annual Meeting of Shareholders

PR Newswire May 8, 2013

Aeterna Zentaris Reports First Quarter 2013 Financial and Operating Results

PR Newswire May 7, 2013